A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

Slides:

Advertisements

Similar presentations

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

Advertisements

Placebo Metformin ***p < vs placebo

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Dandan Wang et al. BTS 2018;3: Diabetes Exacerbates Myocardial Infarction and Ischemia/Reperfusion Injury (A) Comparison of fasting blood glucose.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Urine ammonia is highly correlated with plasma K

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Cellularity of epididymal adipose tissue.

Cyp8b1−/− mice have an altered circulating bile acid pool.

BTG2 regulates gluconeogenic gene expression in diabetic mouse models

Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. Overexpression of BTG2 resulted in an increase in hepatic gluconeogenesis. A:

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Glucose, insulin, and AGE levels during an OGC before and after RT

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Liver AMPK is activated by oral administration of canagliflozin in mice, but this does not explain changes in RER. A: Phosphorylation of AMPK, ACC, and.

Activation of β-adrenoceptors improves glucose tolerance in diabetic animals and increases glucose uptake in vivo, ex vivo, and in vitro. Activation of.

PTx pretreatment abrogates the glucagonostatic effect of high glucose concentrations. PTx pretreatment abrogates the glucagonostatic effect of high glucose.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.

TXNIP and caspase-1 protein levels are increased in the adipose tissue of ob/ob mice. TXNIP and caspase-1 protein levels are increased in the adipose tissue.

Sustained activation of AMPK α2 in muscle of subjects with type 2 diabetes after an overnight withdrawal of metformin. Sustained activation of AMPK α2.

Zn2+ and NAD(P)H content in Mafa∆panc and Mafa∆panc;Mafb+/− β-cells.

Immunoblotting samples (A and F) and densitometric analysis of ASC1 (B and G), NLRP3 (C and H), TNFα (D and I) and Caspase-1 (E and J) expression in the.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.

Somatostatin released by δ-cells exerts a tonic inhibition on glucagon and insulin secretion but is not required for the glucagonostatic effect of glucose.

Linearity of the relationships between spectral abundance factors observed when 30 and 120 μg protein were analyzed, as described in research design and.

Effects of pterosin A on serum levels of lipid, blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT)

The effect of VSG on body weight and body fat in GLP-1r KO mice.

A: Chemical structure of pterosin A

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Rapid improvement of glucose tolerance induced by PP

USP2–45 regulates hepatic gluconeogenesis.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Urinary albumin excretion and histology of glomeruli.

Metabolic effects of VSG in GLP-1r KO mice.

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

High-fat diet–induced glucose intolerance is prevented in ghrelin knockout (Ghr-KO) mice. High-fat diet–induced glucose intolerance is prevented in ghrelin.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Effect of GSK-3 inhibitors on basal and insulin-stimulated glucose uptake in human muscle cells. Effect of GSK-3 inhibitors on basal and insulin-stimulated.

Progressive IGF-1 liver expression, β-cell hyperplasia, and defective insulin secretion with aging in inducible liver-specific insulin receptor knockout.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Study protocol. Study protocol. Eight subjects (seven men and one woman) with type 2 diabetes entered the study. The subjects discontinued their antidiabetic.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

A: Pharmacokinetic (plasma insulin concentration) response to administration of an oral insulin formulation (uninterrupted line) and subcutaneous regular.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). B: The plasma BER in same group of mice. Values (means ± SE) were obtained from each group of seven animals. **P < 0.01 vs. data from animals before treatment. Juei-Tang Cheng et al. Diabetes 2006;55:819-825 ©2006 by American Diabetes Association